Literature DB >> 2067317

[Effects of cyclandelate on the CNS--a double-blind, placebo-controlled study of healthy subjects].

W Dimpfel1, P Netter, M Spüler, W Wedekind.   

Abstract

The effect of cyclandelate (Natil) on the CNS was tested in a double-blind, placebo-controlled pilot study on 48 healthy males using a single oral dosage of 1200 mg. The EEG was evaluated quantitatively by spectral analysis before and one hour as well as two and a half hours after drug or placebo administration under resting conditions and while performing a test of mental arithmetic. Under resting conditions the power in the alpha 2 frequency band of the signals from the frontal and central recordings was increased in the cyclandelate group in comparison to the placebo group. This effect was still observed two and a half hours after drug intake. Under the condition of mental arithmetic no drug related effect was observed in the EEG. The cyclandelate induced increase of spectral power in the alpha 2 frequency band under resting conditions demonstrates a general effect of cyclandelate on the CNS. The results are discussed with respect to the known age related decrease of spectral power in the alpha frequency band. The established effect of cyclandelate in young healthy subjects calls for a study with chronic treatment in elderly subjects or patients with cognitive deficits.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067317     DOI: 10.1007/BF01644765

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  25 in total

1.  RELATION OF EEG TO CEREBRAL BLOOD FLOW AND METABOLISM IN OLD AGE.

Authors:  W D OBRIST; L SOKOLOFF; N A LASSEN; M H LANE; R N BUTLER; I FEINBERG
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1963-08

2.  Orthostatic changes in the EEG power spectra of normal subjects: effect of aging.

Authors:  L A Ivanova
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1988-10

3.  Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents.

Authors:  L Sourander; C B Blakemore
Journal:  Angiology       Date:  1978-02       Impact factor: 3.619

4.  Effect of cyclandelate on cerebral cortex perfusion-rates in cerebrovascular disease.

Authors:  M D O'Brien; N Veall
Journal:  Lancet       Date:  1966-10-01       Impact factor: 79.321

5.  Comparative bioassay of vasoactive drugs using isolated perfused rabbit arteries.

Authors:  J M Van Nueten
Journal:  Eur J Pharmacol       Date:  1969       Impact factor: 4.432

6.  Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.

Authors:  W E Van den Hoven; D W Hall; J W Burns
Journal:  Br J Clin Pract Suppl       Date:  1984

7.  The influence of cyclandelate on Ca++ translocation in human platelets.

Authors:  J W Akkerman; W E van den Hoven
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.

Authors:  M G Albizzati; S Bassi; E Calloni; M Sbacchi; R Piolti; L Frattola
Journal:  Drugs       Date:  1987       Impact factor: 9.546

9.  Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital.

Authors:  W Dimpfel; M Spüler; B Nickel
Journal:  Neuropsychobiology       Date:  1986       Impact factor: 2.328

10.  Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping.

Authors:  B Saletu; P Anderer; K Kinsperger; J Grünberger; W Sieghart
Journal:  Int Clin Psychopharmacol       Date:  1988-10       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.